<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Allogeneic hematopoietic stem cell transplantation is a curative modality for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>; the preferred stem cell source is bone marrow </plain></SENT>
<SENT sid="1" pm="."><plain>However, allogeneic peripheral blood stem cell transplantation (PBSCT) used in high-risk patients is associated with higher risk of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="2" pm="."><plain>Our center receives multitransfused, alloimmunized, infected, late referrals for transplant </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Forty-one patients of median age 22 years (range 8-37) received allogeneic-PBSCT from human leukocyte antigen (HLA)-matched sibling donors </plain></SENT>
<SENT sid="4" pm="."><plain>The median time since diagnosis was 12 months (range 4-65) and median pretransplant transfusions were 37 (range 6-160) </plain></SENT>
<SENT sid="5" pm="."><plain>Six patients were platelet refractory and one alloimmunized for pan-red blood cell (RBC) antigens </plain></SENT>
<SENT sid="6" pm="."><plain>Several patients had pretransplant <z:mp ids='MP_0000611'>icterus</z:mp> or <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> and 26 (63.4%) had unresponsive <z:mp ids='MP_0001794'>bacterial</z:mp>/<z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Our conditioning regimen included fludarabine 30 mg/m(2) for 6 days (days -10 to -5), <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 60 mg/kg/d for 2 days (days -6 to -5), and antithymocyte globulin (ATGAM) 30 mg/kg/d for 4 days (day -4 to -1), which was reduced to 2 days in 2 patients </plain></SENT>
<SENT sid="8" pm="."><plain>We used standard GVHD prophylaxis with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> on days 1, 3, 6, 11 </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: The median follow-up period was 29 months (range 6-78) and median engraftment time 10 days (range 8-17) </plain></SENT>
<SENT sid="10" pm="."><plain>Thirty-one patients (75.6%) were treated for <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, with 20 of these on antifungals for preexisting <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>There were two graft rejections and 10 (24.4%) <z:hpo ids='HP_0011420'>deaths</z:hpo>, with three <z:hpo ids='HP_0002170'>intracranial hemorrhages</z:hpo>, two rejections with <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, three cases of refractory GVHD (<z:hpo ids='HP_0011009'>acute</z:hpo>/<z:e sem="disease" ids="C0410000" disease_type="Disease or Syndrome" abbrv="">overlap syndrome</z:e>) with cytomegalovirus reactivation, and two invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Overall incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was 39% with 2 grade IV cases </plain></SENT>
<SENT sid="13" pm="."><plain>Ten (25%) cases developed <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD, with extensive GVHD in four </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: With more experience using shortened course of ATGAM, HLA-matched donor transfusions, and availability of newer antifungals, we have been able to decrease PBSCT-related mortality </plain></SENT>
<SENT sid="15" pm="."><plain>Further improvement will be possible with early referrals </plain></SENT>
</text></document>